Saturday 17 October 2026
Export TVTX’s income statement to Excel — free account
Travere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 48.2%, EPS fell 164.3%, free cash flow grew 604.2% and total debt rose 93.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
49.60
3.19
−6.04%
Follow TVTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.89 | 6.95 | 5.09 | 8.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 366.95 | |
P/Operating CF |
148.96 | 56.18 | (67.62) | 91.45 | |
P/B ratio |
28.99 | 29.69 | 27.65 | 216.56 | |
Price to Tangible BV |
0.00 | 3,550.82 | 0.00 | 0.00 | |
EV/Sales |
5.02 | 6.92 | 5.18 | 9.17 | |
EV/EBITDA |
0.00 | 0.00 | 208.91 | 269.67 | |
EV/Operating CF |
(37.35) | 89.92 | 70.10 | 58.51 | |
EV/FCF |
(20.30) | (161.30) | (93.71) | 374.80 | |
Quick Ratio |
2.50 | 2.52 | 2.81 | 3.75 | |
Current Ratio |
2.75 | 2.74 | 3.13 | 4.05 | |
Net Debt/EBITDA |
1.40 | 0.65 | (4.05) | 13.87 | |
Debt/Assets |
57.81% | 51.51% | 56.21% | 75.41% | |
Debt/Equity |
4.23 | 2.71 | 3.16 | 24.58 | |
Asset Turnover |
0.84 | 0.82 | 0.97 | 0.87 | |
Operating CF/Net income |
0.56 | 22.23 | 1.09 | (1.67) | |
Capex/Depreciation |
(0.98) | (1.25) | (0.88) | (4.98) | |
Interest Coverage |
9.06 | (14.14) | (16.05) | 1.85 | |
Research and Development Expense of Revenue |
31.48% | 44.62% | 44.89% | 35.55% | |
Selling, General and Administrative Expense of Revenue |
52.44% | 98.51% | 63.09% | 56.68% | |
Intangible Assets out of Total Assets |
0.20 | 0.19 | 0.20 | 0.16 | |
Share Based Compensation of Revenue |
6.83% | 8.84% | 12.69% | 12.85% | |
Graham Net Nets |
(0.04) | (0.02) | (0.02) | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.39%) | (0.76%) | (0.74%) | (0.79%) | |
Free Cash Flow Yield |
(5.06%) | (0.62%) | (1.09%) | 0.27% | |
Revenue per Share |
1.85 | 1.45 | 1.38 | 1.81 | |
Operating CF per Share |
0.16 | 0.68 | (0.44) | 0.62 | |
Capex per Share |
(0.17) | (0.22) | (0.24) | (0.23) | |
Free Cash Flow per Share |
(0.01) | 0.46 | (0.68) | 0.40 | |
Cash per Share |
2.85 | 3.62 | 2.88 | 5.23 | |
Shareholders Equity per Share |
0.82 | 1.29 | 1.07 | 0.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 1.29 | 1.07 | 0.26 | |
Free Cash Flow |
(1.11) | 41.44 | (62.54) | 37.00 | |
Working Capital |
236.04 | 277.66 | 267.24 | 463.12 | |
Capital Expenditures |
(15.42) | (19.24) | (22.18) | (21.07) | |
Net Current Asset Value |
(93.91) | (52.80) | (63.78) | (159.70) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.15 | 0.17 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
54.08 | 53.63 | 60.84 | 59.68 | |
Average Payables |
20.71 | 24.17 | 14.14 | 13.31 | |
Average Inventory |
5.95 | 6.04 | 5.14 | 5.96 | |
Average Assets |
521.50 | 599.66 | 551.99 | 677.33 | |
Average Common Equity |
21.56 | 86.95 | 65.78 | 28.63 |
Columns are period end dates